

20 October 2026

ASX Announcement

CFO Jan Gielen to depart PolyNovo and take up new opportunity

PolyNovo Limited (ASX: PNV) announces that, after almost eight years with the Company, Chief Financial Officer Jan Gielen will step down from his role to pursue a new opportunity as Chief Financial Officer of Vitrafy Life Sciences Limited (ASX: VFY).

Jan Gielen joined PolyNovo in December 2018, at an important stage in the Company's development. Since then, PolyNovo has grown substantially, from total revenue of \$13.7 million in FY19 to \$150.0 million in FY26. Over that period, the Company has significantly expanded its presence in the United States and internationally, launched new products from the NovoSorb® platform, invested in expanded manufacturing capacity and grown to serve patients in more than 50 countries.

Chief Executive Officer Bruce Peatey said:

"Jan has been part of PolyNovo through a remarkable chapter in its history. Over almost eight years, he has helped support the Company through significant growth, international expansion and increasing organisational complexity."

Jan leaves PolyNovo with our genuine thanks and appreciation. He has been a highly valued colleague and leader, and his contribution to the business goes well beyond the numbers. We are very pleased for Jan as he takes this next step and wish him every success."

Jan Gielen said:

"It has been a privilege to be part of PolyNovo's journey over the past eight years. I am deeply grateful to my finance and IT team for their support and significant contribution, and incredibly proud of what the entire PolyNovo team has achieved, including the impact our technology is having on patients around the world. I leave with enormous respect for the people at PolyNovo and great confidence in the Company's future."

PolyNovo has engaged an external firm to assist with the appointment of an interim CFO, while the Company commences a comprehensive search for Jan Gielen's permanent successor. Jan Gielen will remain with the Company until 15 January 2027 to support a smooth transition.

The Board and the entire PolyNovo team thank Jan Gielen for his significant contribution to the Company and wish him every success in his new role.

This announcement has been authorised for release by PNV's Company Secretary, Amy Demediuk.

Further information:


Amy Demediuk, General Counsel & Company Secretary

Mobile: + 61 419 858 691

Email: amy.d@polynovo.com



PolyNovo Limited (ASX: PNV) ABN 96 083 866 862
2/320 Lorimer Street, Port Melbourne, Victoria 3207 Australia
+61 3 8681 4050 investor@polynovo.com
investors.polynovo.com



About PolyNovo®

PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners.

The proprietary NovoSorb® polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets.

Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth.

For more information see polynovo.com

[View this announcement on PolyNovo's investor hub](#)